Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Pharmazz and Sun Pharmaceutical Industries Enter into Agreement

Thursday, September 14, 2023

Pharmazz has entered into a licence agreement with Sun Pharmaceutical Industries to introduce Tyvalzi™ (Sovateltide) in India.

Under the terms of the agreement, Sun Pharma has been granted the rights to market Sovateltide in India, utilising the brand name Tyvalzi™ (Sovateltide). In return, Pharmazz will receive upfront and milestone payments, including royalties.

Tyvalzi™ is a new drug designed to address acute cerebral ischaemic stroke, a condition characterised by the interruption of blood supply to the brain, leading to potential brain damage, neurological deficits, or even death.

The mechanism of action of Tyvalzi™ involves the promotion of neurovascular remodelling, including the formation of new neurons (neurogenesis) and blood vessels (angiogenesis). Additionally, it offers protection to neural mitochondria and enhances their biogenesis.

Sovateltide (Tyvalzi™) has been approved as a new, effective, and well-tolerated therapy for treating patients with cerebral ischaemic stroke. It has shown statistically significant and clinically meaningful improvements in neurological outcomes.

Currently, there have been no new drugs approved for the treatment of stroke in over two decades, aside from rTPA. Sovateltide (Tyvalzi™), as a selective endothelin B receptor agonist, represents a groundbreaking development and can be administered up to 24 hours following a cerebral ischaemic stroke.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024